Intellectual Property Due Diligence

Lead hundreds of investor-side and company-side IP due diligence reviews each year

 

Myovant Sciences Acquired by Sumitovant Biopharma

Learn more

Myovant Sciences Acquired by Sumitovant Biopharma

November 4, 2022

Cooley has worked with Myovant Sciences since 2017 to develop and prosecute its owned and licensed patent portfolios and in intellectual property diligence leading up to Myovant’s acquisition by biopharmaceutical company, Sumitovant Biopharma. The total transaction value was $1.7 billion, with a total company value of $2.9 billion. Myovant aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy.

"Myovant's two products, ORGOVYX® and MYFEMBREE® have substantial potential. We believe the combination of Sumitovant and Myovant will strengthen Myovant's product capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women's health," said Hiroshi Nomura, CEO of Sumitomo Pharma. "

Related contacts

Mika Reiner Mayer
Partner, Palo Alto
Kimberly Bolin
Patent Agent, Palo Alto

Why Cooley

  • One of the largest full-service IP teams of any law firm, with 200+ dedicated IP lawyers and patent professionals across the US and UK

  • Regularly called upon to lead investor-side and company-side IP due diligence surrounding investments, M&A deals, capital market offerings and other high-value deals and transactions

  • With deep understanding of what creates commercial value in an IP portfolio, we are adept at simplifying the complex by translating IP risks into business risks

  • Robust, full-service life sciences and technology platforms allow for seamless collaboration with lawyers across related areas including venture financing, licensing, litigation, FDA/regulatory, strategic transactions and collaboration deals

Read more

Law Firm of the Year for Startups

The Recorder

Recognition

  • BTI Consulting: Top 5 law firm for client service and for best value (per dollar of legal spend)
  • Chambers, Legal 500: Top IP and life sciences practices in the US and UK
  • Docket Navigator: Top law firm for PTAB proceedings
  • IAM Patent 1000: Top patent prosecution firm
  • LMG Life Sciences: 2022 “Patent Strategy and Management Firm of the Year” Honoree
  • Managing Intellectual Property: Top patent prosecution firm
  • US News and World Report: Tier 1 firm for patent law

Group Contacts

Dr. Fraser Brown
Partner
Washington, DC
Scott Dailard
Partner
San Diego
Bobby Ghajar
Partner
Santa Monica
Dr. Chris Holly
Partner
Washington, DC
Brendan Hughes
Co-Partner in Charge – Washington, DC
Washington, DC
Christopher Hutter
Partner
Reston
Dr. Carol Laherty
Partner
Seattle
Mika Reiner Mayer
Partner
Palo Alto
Colm Murphy
Partner
London
John Paul Oleksiuk
Partner
New York
Dr. Madhuri Roy
Partner
Palo Alto
Scott Talbot
Senior Counsel
Reston
Dr. Michael Tuscan
Partner
Washington, DC
Scott Weston
Partner
Boston

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.